

Public Workshop on COVID-19 Lessons Learned: Clinical Evaluation of Therapeutics

September 28, 2021 1-5:30pm Eastern

Agenda

| 1pm | Welcome and Introduction | |
|---|---|--|
| Kevin Bugin, PhD, Acting Deputy Director of Operations, Office of New Drugs, Center for Drug Evaluation and Research, FDA; Former Therapeutics Chief of Staff, Federal COVID-19 Response or Countermeasures Acceleration Groups (formerly known as Operation Warp Speed) Susan C. Winckler, RPh, Esq., CEO, Reagan-Udall Foundation for the FDA | | |
| 1:15pm | Opening Plenary | |
| Janet Woodcock, MD, Acting Commissioner of Food and Drugs, FDA Francis S. Collins, MD, PhD, Director, National Institutes of Health | | |
| 1:45pm | Research, Scoping, & Prioritization Panel | |
| Moderated by Stacey Adam, PhD, Associate Vice President, Research Partnerships, Foundation for the National Institutes of Health Michael Santos, PhD, Vice President, Science, Foundation for the National Institutes of Health | | |
| Panelists: Janet Woodcock, MD, Acting Commissioner of Food and Drugs, FDA Phyllis Arthur, MBA, Vice President, Infectious Diseases & Diagnostics Policy, BIO Elliott Levy, MD, COVID R&D Consortium Sarah Read, MD, Deputy Director, Division of AIDS, National Institute of Allergy and Infectious Diseases and Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) Therapeutics-Clinical Work Group Co-Chair | | |
| 2:45pm | Infrastructure & Resourcing Panel | |
| | Moderated by Esther Krofah, Executive Director, FasterCures and Center for Public Health, Milken Institute Kristin Schneeman, Director, FasterCures, Milken Institute | |
| H M Ti Ja | arbara Bierer, MD, Faculty Director, Multi-Regional Clinical Trials Center of Brigham and Women's ospital and Harvard; Professor of Medicine, Harvard Medical School and Brigham and Women's Hospital lichael Kurilla, MD, PhD, Director, Division of Clinical Innovation, National Center for Advancing ranslational Sciences, National Institutes of Health Imes Mayne, Vice President, Science Advocacy, PhRMA oug Peddicord, PhD, Executive Director, Association of Clinical Research Organizations | |
| 3:45pm | Clinical Trial Execution Panel | |
| Moderated by Mark McClellan, MD, PhD, Robert J. Margolis Professor of Business, Medicine, and Policy, and founding Director of the Duke-Margolis Center for Health Policy, Duke University Sarah Sheehan, MPA, Managing Associate, Duke Margolis Center for Health Policy | | |

Panelists:

- Samuel Brown, MD, MS, Attending Physician, Intermountain Medical Center and Assistant Professor of Pulmonary and Critical Care, University of Utah School of Medicine Intermountain
- Janice Chang, Chief Operating Officer, TransCelerate BioPharma Inc.
- Monica Webb Hooper, PhD, Deputy Director, National Institute on Minority Health and Health Disparities
- Kate Zenlea, MPH, CPH, Managing Director, The Global Health Initiative at Henry Ford Health System

| 4:45pm | Public Comment |
|--|-----------------|
| Open to those who submitted comments in Docket; time permitting | |
| 5:15pm | Closing Plenary |
| Kevin Bugin, PhD, Acting Deputy Director of Operations, Office of New Drugs, Center for Drug Evaluation and | |
| Research, FDA; Former Therapeutics Chief of Staff, Federal COVID-19 Response or Countermeasures Acceleration | |
| Groups (formerly known as Operation Warp Speed) | |